Meet The Professors Live: Volume 1, Issue 1
Based on the proceedings of a live tumor panel
discussion
on the management of early and
advanced breast cancer
| Moderator: |
|
|
 |
| Neil Love, MD |
|
|
| |
|
|
|
Faculty: |
|
|
| Howard A Burris III, MD |
Julie R Gralow, MD |
|
| Professor John Crown, MD |
Clifford Hudis, MD |
|
| Kevin R Fox, MD |
Antonio C Wolff, MD |
|
|
CME INFORMATION
FACULTY AFFILIATIONS AND DISCLOSURES
Case 1: A 29-year-old nursing student underwent a right mastectomy for two 3-cm,
Grade III, ER-positive, PR-positive, HER2-positive infiltrating ductal cancers
(IDC) in the right breast. Five axillary nodes were positive, and the patient
is now being considered for adjuvant systemic therapy (from the practice of
Alan B Astrow, MD).
Case 2: A 39-year-old woman at 21 weeks’ gestation with her second pregnancy
presented with a 4 x 3.1-cm, triple-negative IDC and a palpable lymph node
that was positive for malignant cells on FNA. The tumor is BRCA1-positive,
and the patient’s mother died of breast cancer at the age of 29. The patient
desires breast-conserving surgery, but the surgeon states that tumor shrinkage
would be required (from the practice of Mary Ann K Allison, MD).
Case 3: A 77-year-old otherwise healthy physician’s wife presented with a 5.5-cm, left-sided,
ER-positive, PR-positive, HER2-negative infiltrating lobular carcinoma
with one of three positive sentinel nodes. The patient wishes to avoid
chemotherapy, if possible (from the practice of Robert A Moss, MD).
Case 4: A 61-year-old woman who was treated with adjuvant AC and five years of
tamoxifen for left-sided, node-positive breast cancer presented eight years
after initial diagnosis with biopsy-proven metastatic disease to the left lung.
She was treated with letrozole for three years, then developed symptomatic
progression with mediastinal and hilar lymph node metastases, for which she
received radiation therapy and fulvestrant. After disease progression, the
patient was treated with capecitabine but developed a malignant pericardial
effusion, treated with a pericardial window (from the practice of Dr Astrow).
Case 5: A 58-year-old woman with a 4-cm, Grade III, ER-negative, HER2-positive IDC
and synchronous bone and liver metastases was enrolled on the TORI B-03
trial of trastuzumab and bevacizumab. She experienced tumor response and
disease stabilization for two years, at which time she desired less frequent
therapy and was treated off study with trastuzumab alone every three weeks.
She received further lines of chemotherapy/anti-HER2 treatment upon disease
progression and was intolerant of lapatinib because of intractable diarrhea.
She then developed back pain from progressive bone metastases (from the
practice of Dr Allison).
Case 6: A 69-year-old emotionally fragile woman who underwent mastectomy and
undetermined “low-dose chemotherapy” 14 years earlier for right-sided,
node-negative breast cancer presented with a chest wall abnormality. Biopsy
revealed a poorly differentiated, ER-positive, PR-negative, HER2-negative
adenocarcinoma consistent with primary breast cancer. MRI revealed extensive
right chest wall involvement, including skin, pectoral muscles and axillary
nodes. The chest wall was indurated, erythematous and pruritic (from the
practice of Dr Moss).
Case 7: A 41-year-old nurse who underwent mantle radiation therapy 21 years ago
for Stage IIA Hodgkin disease presented with a 1.3-cm, poorly differentiated,
triple-negative, p53-positive, node-negative breast cancer (presented by an
audience member).
Select Publications
|
|
